Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afinitor plus carboplatin in triple-negative metastatic breast cancer
NCT01127763Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in triple negative breast cancer (TNBC), sponsored by NYU Langone Health. Started Jun 2010; status: completed.
02
Drugs
everolimus
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01127763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127763.